El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and ...

Counterfeit versions of Wegovy or Zepbound are different from compounded ... They are manufactured and packaged to look like legitimate brand-name medications, but often contain little to none ...

Imagine being one of the millions of Americans in need of a hip or knee replacement due to osteoarthritis. Severe pain, ...

I had been taking Zepbound for about six months when it clicked. My period — the monster that turned me from a functioning ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Losing weight by dieting (restricting energy) includes, along with fat loss, losing lean mass, about half of which is ...

Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

We recently compiled a list of the Billionaire Israel Englander’s Top 10 Stock Picks Heading Into 2025. In this article, we ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...